Lamotrigine
Lamictal · Subvenite
The precise mechanism(s) by which lamotrigine exerts its anticonvulsant action are unknown. In animal models designed to detect anticonvulsant activity, lamotrigine was effective in preventing seizure spread in the maximum electroshock (MES) and pentylenetetrazol (scMet) tests, and prevented seizures in the visually and electrically evoked after-discharge (EEAD) tests for antiepileptic activity. Lamotrigine also displayed inhibitory properties in the kindling model in rats both during kindling development and in the fully kindled state. The relevance of these models to human epilepsy, however, is not known. One proposed mechanism of action of lamotrigine, the relevance of which remains to be established in humans, involves an effect on sodium channels. In vitro pharmacological studies suggest that lamotrigine inhibits voltage-sensitive sodium channels, thereby stabilizing neuronal membranes and consequently modulating presynaptic transmitter release of excitatory amino acids (e.g., glutamate and aspartate). Effect of Lamotrigine on N-Methyl d-Aspartate-Receptor Mediated-Activity Lamotrigine did not inhibit N-methyl d-aspartate (NMDA)-induced depolarizations in rat cortical slices or NMDA-induced cyclic GMP formation in immature rat cerebellum, nor did lamotrigine displace compounds that are either competitive or noncompetitive ligands at this glutamate receptor complex (CNQX, CGS, TCHP). The IC 50 for lamotrigine effects on NMDA-induced currents (in the presence of 3 μM of glycine) in cultured hippocampal neurons exceeded 100 μM. The mechanisms by which lamotrigine exerts its therapeutic action in bipolar disorder have not been established.
Compare Lamotrigine →FDA-Approved Indications
- Epilepsy — adjunctive (partial-onset, PGTC, Lennox-Gastaut; 2+ years)
- Epilepsy — conversion to monotherapy (partial-onset; 16+ years)
- Bipolar I maintenance — delay mood episode recurrence (adults)
Common Off-Label Uses
- Treatment-resistant depression (unipolar)
- PTSD
- Borderline personality disorder
- Neuropathic pain
What Sets This Drug Apart
- First-line mood stabilizer for bipolar depression maintenance and depressive-pole prevention; does NOT induce mania or rapid cycling
- Lowest teratogenicity among mood stabilizers: Tomson 2018 EURAP 2.9% (≤325 mg/day: 2.5%, reference-lowest AED dose category)
- MANDATORY very slow titration to minimize SJS/TEN risk (0.08-0.13% in bipolar): ~25 mg/week standard; halve to ~12.5 mg/week with valproate co-administration
- SJS/TEN risk is the FDA BOXED WARNING; risk factors include valproate co-administration, rapid titration, and exceeding recommended dose escalation
- UGT1A4 substrate — valproate doubles lamotrigine levels (halve dose); enzyme inducers (carbamazepine) halve levels (double dose)
- No significant metabolic effects: weight-neutral, no hepatotoxicity concern, no blood monitoring requirement beyond clinical assessment
- Not effective as monotherapy for acute mania — specifically a maintenance and depression-prevention agent